69C Stock Overview

Operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases. More details

69C fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Tvardi Therapeutics, Inc. Competitors

PharmaSGP Holding

XTRA:PSG

€274.0m

MPH Health Care

DB:93M1

€106.2m

Apontis Pharma

XTRA:APPH

€93.3m

Cantourage Group

XTRA:HIGH

€61.1m

Price History & Performance

Summary of share price highs, lows and changes for Tvardi Therapeutics
Historical stock prices
Current Share Price	US$22.70
52 Week High	US$24.20
52 Week Low	US$14.81
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	53.32%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	69C	DE Pharmaceuticals	DE Market
7D	14.8%	2.2%	2.5%
1Y	n/a	-17.6%	13.4%

Return vs Industry: Insufficient data to determine how 69C performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 69C performed against the German Market.

Price Volatility

Is 69C's price volatile compared to industry and market?
69C volatility
69C Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.0%
Market Average Movement	6.4%
10% most volatile stocks in DE Market	12.9%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: 69C's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 69C's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2017	n/a	Imran Alibhai	tvarditherapeutics.com

Tvardi Therapeutics, Inc. operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases. It develops inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis. Its pipeline includes TTI-101, a small-molecule inhibitor of signal transducers and activators of transcription; and TTI-109, a STAT3 inhibitor for clinical use, including tolerability, bioavailability, and potency.

Tvardi Therapeutics, Inc. Fundamentals Summary

How do Tvardi Therapeutics's earnings and revenue compare to its market cap?
69C fundamental statistics
Market cap	€217.10m
Earnings (TTM)	€0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is 69C overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
69C income statement (TTM)
Revenue	€0
Cost of Revenue	€0
Gross Profit	€0
Other Expenses	€0
Earnings	€0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did 69C perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/07 23:25
End of Day Share Price	2025/05/07 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tvardi Therapeutics, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Debanjana Chatterjee	JonesTrading Institutional Services, LLC
Christopher Liu	Lucid Capital Markets